Apex Biotechnology Corp. Statistics
Apex Biotechnology Corp. (1733) Stock Statistics & Valuation Metrics
Total Valuation
Apex Biotechnology Corp. has a market cap or net worth of TWD 2.88B. The enterprise value is TWD 2.27B.
- Market Cap
- TWD 2.88B
- Enterprise Value
- TWD 2.27B
Share Statistics
Apex Biotechnology Corp. has 99,950,195 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 99,950,195
- Owned by Insiders
- ―
- Owned by Institutions
- 0.20%
Financial Efficiency
Apex Biotechnology Corp.’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 5.95%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 5.95%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 3.03M
- Profits Per Employee
- 254.35K
- Employee Count
- 641
- Asset Turnover
- 0.81
- Inventory Turnover
- 2.50
Valuation Ratios
The current PE Ratio of Apex Biotechnology Corp. is 15.13. Apex Biotechnology Corp.’s PEG ratio is 0.91.
- PE Ratio
- 15.13
- PS Ratio
- 1.54
- PB Ratio
- 1.55
- Price to FCF
- 11.18
- Price to Operating Cash Flow
- 10.40
- PEG Ratio
- 0.91
Income Statement
In the last 12 months, Apex Biotechnology Corp. had revenue of 1.94B and earned 163.04M in profits. Earnings per share was 1.63.
- Revenue
- 1.94B
- Gross Profit
- 538.74M
- Operating Income
- 140.73M
- Pretax Income
- 189.90M
- Net Income
- 163.04M
- EBITDA
- 201.65M
- Earnings Per Share (EPS)
- 1.63
Cash Flow
In the last 12 months, operating cash flow was 277.65M and capital expenditures -20.72M, giving a free cash flow of 256.92M billion.
- Operating Cash Flow
- 277.65M
- Free Cash Flow
- 256.92M
- Free Cash Flow per Share
- 2.56
Dividends & Yields
Apex Biotechnology Corp. pays an annual dividend of ―, resulting in a dividend yield of 4.51%
- Dividend Per Share
- ―
- Dividend Yield
- 4.51%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 8.94%
- Earnings Yield
- 6.60%
Stock Price Statistics
- Beta
- 0.15
- 52-Week Price Change
- -9.56%
- 50-Day Moving Average
- 30.23
- 200-Day Moving Average
- 29.50
- Relative Strength Index (RSI)
- 35.22
- Average Volume (3m)
- 111.79K
Important Dates
Apex Biotechnology Corp. upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Apex Biotechnology Corp. as a current ratio of 3.87, with Debt / Equity ratio of 7.96%
- Current Ratio
- 3.87
- Quick Ratio
- 2.57
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -2.07
- Interest Coverage Ratio
- 41.54
Taxes
In the past 12 months, Apex Biotechnology Corp. has paid 26.86M in taxes.
- Income Tax
- 26.86M
- Effective Tax Rate
- 0.14
Enterprise Valuation
Apex Biotechnology Corp. EV to EBITDA ratio is 10.05, with an EV/FCF ratio of 8.87.
- EV to Sales
- 1.22
- EV to EBITDA
- 10.05
- EV to Free Cash Flow
- 8.87
- EV to Operating Cash Flow
- 8.21
Balance Sheet
Apex Biotechnology Corp. has TWD 814.85M in cash and marketable securities with TWD 144.11M in debt, giving a net cash position of TWD 670.74M billion.
- Cash & Marketable Securities
- TWD 814.85M
- Total Debt
- TWD 144.11M
- Net Cash
- TWD 670.74M
- Net Cash Per Share
- TWD 6.71
- Tangible Book Value Per Share
- TWD 18.18
Margins
Gross margin is 30.39%, with operating margin of 9.27%, and net profit margin of 10.21%.
- Gross Margin
- 30.39%
- Operating Margin
- 9.27%
- Pretax Margin
- 11.73%
- Net Profit Margin
- 10.21%
- EBITDA Margin
- 12.16%
- EBIT Margin
- 10.45%
Analyst Forecast
The average price target for Apex Biotechnology Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -8.15%
- EPS Growth Forecast
- 17.27%
